Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2016 1
2017 1
2018 3
2019 3
2020 1
2021 1
2022 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

13 results

Results by year

Filters applied: . Clear all
Page 1
Antibodies Targeting Chemokine Receptors CXCR4 and ACKR3.
Bobkov V, Arimont M, Zarca A, De Groof TWM, van der Woning B, de Haard H, Smit MJ. Bobkov V, et al. Mol Pharmacol. 2019 Dec;96(6):753-764. doi: 10.1124/mol.119.116954. Epub 2019 Sep 3. Mol Pharmacol. 2019. PMID: 31481460 Review.
Conformational selection guides β-arrestin recruitment at a biased G protein-coupled receptor.
Kleist AB, Jenjak S, Sente A, Laskowski LJ, Szpakowska M, Calkins MM, Anderson EI, McNally LM, Heukers R, Bobkov V, Peterson FC, Thomas MA, Chevigné A, Smit MJ, McCorvy JD, Babu MM, Volkman BF. Kleist AB, et al. Among authors: bobkov v. Science. 2022 Jul 8;377(6602):222-228. doi: 10.1126/science.abj4922. Epub 2022 Jul 7. Science. 2022. PMID: 35857540 Free PMC article.
Nanobodies: New avenues for imaging, stabilizing and modulating GPCRs.
De Groof TWM, Bobkov V, Heukers R, Smit MJ. De Groof TWM, et al. Among authors: bobkov v. Mol Cell Endocrinol. 2019 Mar 15;484:15-24. doi: 10.1016/j.mce.2019.01.021. Epub 2019 Jan 26. Mol Cell Endocrinol. 2019. PMID: 30690070 Free article. Review.
CXCR4-targeting nanobodies differentially inhibit CXCR4 function and HIV entry.
Van Hout A, Klarenbeek A, Bobkov V, Doijen J, Arimont M, Zhao C, Heukers R, Rimkunas R, de Graaf C, Verrips T, van der Woning B, de Haard H, Rucker JB, Vermeire K, Handel T, Van Loy T, Smit MJ, Schols D. Van Hout A, et al. Among authors: bobkov v. Biochem Pharmacol. 2018 Dec;158:402-412. doi: 10.1016/j.bcp.2018.10.015. Epub 2018 Oct 17. Biochem Pharmacol. 2018. PMID: 30342024
Advanced fluorescence microscopy reveals disruption of dynamic CXCR4 dimerization by subpocket-specific inverse agonists.
Işbilir A, Möller J, Arimont M, Bobkov V, Perpiñá-Viciano C, Hoffmann C, Inoue A, Heukers R, de Graaf C, Smit MJ, Annibale P, Lohse MJ. Işbilir A, et al. Among authors: bobkov v. Proc Natl Acad Sci U S A. 2020 Nov 17;117(46):29144-29154. doi: 10.1073/pnas.2013319117. Epub 2020 Nov 4. Proc Natl Acad Sci U S A. 2020. PMID: 33148803 Free PMC article.
Correction: Zakrzewicz et al. Stabilization of Keratinocyte Monolayer Integrity in the Presence of Anti-Desmoglein-3 Antibodies through FcRn Blockade with Efgartigimod: Novel Treatment Paradigm for Pemphigus? Cells 2022, 11, 942.
Zakrzewicz A, Würth C, Beckert B, Feldhoff S, Vanderheyden K, Foss S, Andersen JT, Haard H, Verheesen P, Bobkov V, Tikkanen R. Zakrzewicz A, et al. Among authors: bobkov v. Cells. 2022 May 20;11(10):1700. doi: 10.3390/cells11101700. Cells. 2022. PMID: 35626757 Free PMC article.
Nanobody-Fc constructs targeting chemokine receptor CXCR4 potently inhibit signaling and CXCR4-mediated HIV-entry and induce antibody effector functions.
Bobkov V, Zarca AM, Van Hout A, Arimont M, Doijen J, Bialkowska M, Toffoli E, Klarenbeek A, van der Woning B, van der Vliet HJ, Van Loy T, de Haard H, Schols D, Heukers R, Smit MJ. Bobkov V, et al. Biochem Pharmacol. 2018 Dec;158:413-424. doi: 10.1016/j.bcp.2018.10.014. Epub 2018 Oct 17. Biochem Pharmacol. 2018. PMID: 30342023 Free article.
13 results